Cancer Nanotechnology

Symposium Co-Chairs

Mansoor M. Amiji
Distinguished Professor & Chair, Dept. of Pharmaceutical Sciences, Co-Director, Nanomedicine Education & Research Consortium
Northeastern University

Anil Patri
Director, NCTR/ORA NanoCore, National Center for Toxicological Research
U.S. Food and Drug Administration

Key Speakers

Targeting Approaches to Address the Spectrum of Hot and Cold Tumors
Puja Sapra
Senior Director, Oncology Research Unit, Pfizer

Nanophysics in oncology: an individualized mass medicine approach
Laurent Levy
President and Chief Executive Officer, Nanobiotix SA

Achieving Effective Vascular and Extravascular Targeted Drug Delivery with Lipid Nanoparticles and Micelles
Gregory Lanza
Professor, Washington University School of Medicine

Integrated Nanoplatform for Cancer imaging and Treatment
Samuel Achilefu
Director, Optical Radiology Laboratory, Michel M. Ter-Pogossian Endowed Chair in Radiology, Washington University School of Medicine

Nanotechnology has the potential to have a revolutionary impact on cancer diagnosis and therapy. It is universally accepted that early detection of cancer is essential even before anatomic anomalies are visible. A major challenge in cancer diagnosis in the 21st century is to be able to determine the exact relationship between cancer biomarkers and the clinical pathology, as well as, to be able to non-invasively detect tumors at an early stage for maximum therapeutic benefit. For breast cancer, for instance, the goal of molecular imaging is to be able to accurately diagnose when the tumor mass has approximately 100-1000 cells, as opposed to the current techniques like mammography, which require more than a million cells for accurate clinical diagnosis.

In cancer therapy, targeting and localized delivery are the key challenges. To wage an effective war against cancer, we have to have the ability to selectively attack the cancer cells, while saving the normal tissue from excessive burdens of drug toxicity. However, because many anticancer drugs are designed to simply kill cancer cells, often in a semi-specific fashion, the distribution of anticancer drugs in healthy organs or tissues is especially undesirable due to the potential for severe side effects. Consequently, systemic application of these drugs often causes severe side effects in other tissues (e.g. bone marrow suppression, cardiomyopathy, neurotoxicity), which greatly limits the maximal allowable dose of the drug. In addition, rapid elimination and widespread distribution into non-targeted organs and tissues requires the administration of a drug in large quantities, which is often not economical and sometimes complicated due to non-specific toxicity. This vicious cycle of large doses and the concurrent toxicity is a major limitation of current cancer therapy. In many instances, it has been observed that the patient succumbs to the ill effects of the drug toxicity far earlier than the tumor burden.

This symposium will address the potential ways in which nanotechnology can address these challenges. Distinguished speakers will summarize the current state of the art and future barriers. Contributions are also solicited in the following topics.

Platinum Sponsors